Kostas Biliouris
Stock Analyst at Oppenheimer
(0.97)
# 3,947
Out of 5,152 analysts
64
Total ratings
30.77%
Success rate
-18.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEPG PepGen | Initiates: Outperform | $15 | $5.51 | +172.48% | 1 | Feb 25, 2026 | |
| KRRO Korro Bio | Upgrades: Outperform | $22 | $10.95 | +100.91% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $26.34 | +135.38% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $16.23 | +208.07% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $320.51 | +46.64% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $75.16 | -6.87% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.37 | +191.97% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $4.64 | +72.41% | 2 | May 28, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $15.20 | +228.95% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.49 | +355.79% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $13.15 | +280.23% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $4.53 | +650.55% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.61 | +955.90% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $8.64 | +362.96% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $17.75 | +407.04% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $25.52 | +123.35% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $66.17 | -44.08% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $60.57 | +65.10% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.93 | +383.46% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $57.33 | +70.94% | 1 | Jun 17, 2022 |
PepGen
Feb 25, 2026
Initiates: Outperform
Price Target: $15
Current: $5.51
Upside: +172.48%
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $10.95
Upside: +100.91%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $26.34
Upside: +135.38%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $16.23
Upside: +208.07%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $320.51
Upside: +46.64%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $75.16
Upside: -6.87%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.37
Upside: +191.97%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $4.64
Upside: +72.41%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $15.20
Upside: +228.95%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.49
Upside: +355.79%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $13.15
Upside: +280.23%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.53
Upside: +650.55%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.61
Upside: +955.90%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $8.64
Upside: +362.96%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $17.75
Upside: +407.04%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $25.52
Upside: +123.35%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $66.17
Upside: -44.08%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $60.57
Upside: +65.10%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.93
Upside: +383.46%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $57.33
Upside: +70.94%